Drug discovery and NCEs

In 2018 FDA has approved 34 new drugs which are presently in the market. Each year, CDER approves series of new drugs and biological products. Some of these products are often innovative new products that never before have been used in clinical practice. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. According to Medscape the ratio of researched drugs to eventually approved therapies at between 5,000-to-1 and 10,000-to-1. Nonetheless, if a drug manages to gain FDA approval, the cumulative direct and indirect expenses are huge.  As per estimated study performed by a well-known university, the true cost to bring a drug to market was US$2.56 billion. This figure is inclusive of just shy of $1.4 billion in average out-of-pocket costs to the drug developer, as well as $1.16 billion in time costs, which are essentially the expected returns that investors forgo while a drug is in development.

 

  • Computer Aided Drug Design (CADD)
  • Insilco Drug Discovery
  • Novel Detection Technologies and Drug Discovery
  • New Chemical Entity Exclusivity Determinations
  • Statutory and regulatory framework
  • NME versus NCE

Related Conference of Drug discovery and NCEs

August 19-20, 2019

24th World Congress on Pharmacology

Vienna, Austria
September 11-12, 2019

14th World Congress on Pharmacology and Toxicology

Singapore
September 11-12, 2019

World Congress on Drug Discovery and Drug Design

Singapore
September 25-26, 2019 Hong Kong

17th World Congress on Drug Formulation & Drug Delivery

Courtyard by Marriott Hong kong
October 07-08 2019

Global Congress on Pharmacology and Therapeutics

Paris, France
October 07-08, 2019

Innovation in Drug Design Techniques and pharmacology

| Paris, France
October 10-11, 2019

15th World Congress on Medicinal Chemistry & CADD

Dubrovnik | Croatia
October 14-15, 2019

19th World Congress on Advances in Pharmaceutical Sciences

Seoul, South Korea
Oct 23-24 2019

11th Annual Biomarkers and Clinical Research Congress

| Amsterdam, Netherlands
October 25-26, 2019

14th International Conference on Biopharma and Biotherapeutics

| Copenhagen, Denmark
October 23-24, 2019 | Copenhagen, Denmark

12th Pharma Congress

November 04-05, 2019

Advanced Pharmaceutics and Clinical Research

| Paris, France
September 11-12, 2019

2nd Annual Pharmaceutical Biotechnology Congress

Singapore
November 11-12, 2019

20th Annual Pharma Middle East Congress

Istanbul, Turkey
November 18-19, 2019

European Congress on Nanomedicine and Pharmaceutical Nanotechnology

Prague, Czech Republic
November 18-19, 2019

European Conference on Pharmacovigilance & Drug Safety

Prague, Czech Republic
November 18-19, 2019

27th Global Experts Meeting on Neuropharmacology

Rome, Italy
November 19-20, 2019

20th Annual Meet on Pharmaceutical Sciences

Bangkok, Thailand
December 02-03, 2019

15th Annual Congress on Pharmacology and Toxicology

Paris, France
March 23-24, 2020

23rd Asia Pacific Pharma Congress

Singapore
April 01-02, 2020

13th European Biosimilars Congress 2020

London, Uk
April 22-23, 2020

5th Pharmaceutical Chemistry Conference

Prague, Czech Republic
April 27-28, 2020

7th European Biopharma Congress

Prague, Czech Republic
May 06-07, 2020

15th Annual Meet on Euro Ethnopharmacology

Prague | Czech Republic
May 18-19, 2020

22nd Annual European Pharma Congress

Berlin, Germany

Drug discovery and NCEs Conference Speakers

Recommended Sessions

Related Journals

Are you interested in